Atossa Therapeutics (NASDAQ:ATOS) Posts Earnings Results, Beats Expectations By $0.02 EPS

Atossa Therapeutics (NASDAQ:ATOSGet Free Report) released its quarterly earnings results on Monday. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.07) by $0.02, Zacks reports.

Atossa Therapeutics Stock Performance

Shares of ATOS stock traded up $0.07 on Wednesday, hitting $1.61. The stock had a trading volume of 1,208,155 shares, compared to its average volume of 1,399,000. Atossa Therapeutics has a one year low of $0.62 and a one year high of $2.31. The business has a 50 day moving average price of $1.58 and a 200 day moving average price of $1.10.

Insider Buying and Selling at Atossa Therapeutics

In other Atossa Therapeutics news, Director Jonathan Finn acquired 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 10th. The shares were bought at an average cost of $1.77 per share, with a total value of $44,250.00. Following the completion of the acquisition, the director now directly owns 25,000 shares in the company, valued at approximately $44,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 7.80% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. StockNews.com upgraded Atossa Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Atossa Therapeutics in a report on Tuesday. Finally, HC Wainwright raised their target price on shares of Atossa Therapeutics from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Monday.

Check Out Our Latest Stock Report on ATOS

Atossa Therapeutics Company Profile

(Get Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Further Reading

Earnings History for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.